Ajanta Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE031B01049
  • NSEID: AJANTPHARM
  • BSEID: 532331
INR
2,630.30
4.05 (0.15%)
BSENSE

Dec 05

BSE+NSE Vol: 54.48 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Ajanta Pharma Ltd. stock-summary
stock-summary
Ajanta Pharma Ltd.
Mid Cap
Pharmaceuticals & Biotechnology
Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments.
Company Coordinates stock-summary
Company Details
Ajanta House, Charkop Kandivli (W) Mumbai Maharashtra : 400067
stock-summary
Tel: 91-22-66061000/1204/1203
stock-summary
info@ajantapharma.com
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 24.98 Cr
Number of Shares
12.49 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
30-Jul-2024
12.49
24.98
24325
2
Issued under ESOP Scheme
27-Jun-2024
12.49
24.98
-1028881
2
Buy Back of Shares
02-May-2024
12.59
25.18
1000
2
Issued under ESOP Scheme
05-May-2023
12.81
25.63
1000
2
Issued under ESOP Scheme
05-May-2023
12.59
25.18
1000
2
Issued under ESOP Scheme
19-Apr-2023
12.59
25.18
-2210500
2
Buy Back of Shares
22-Jun-2022
12.81
25.63
42708385
2
Bonus Issue
10-May-2022
8.54
17.08
1000
2
Issued under ESOP Scheme
26-Feb-2022
8.54
17.08
-1120000
2
Buy Back of Shares
24-Sep-2021
8.65
17.31
4000
2
Issued under ESOP Scheme
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

15.2771

Mutual Funds

Held by 29 Schemes (14.67%)

FIIs

Held by 282 FIIs (8.53%)

Promoter with highest holding

Rajesh M Agrawal, Trustee Rajesh Agrawal Trust (14.47%)

Highest Public shareholder

Uti-flexi Cap Fund (3.12%)

Individual Investors Holdings

6.53%

stock-summary Board of Directorsstock-summary
stock-summary
Management
Designation
Remuneration
Mannalal B Agrawal
Chairman (Non-Executive)
7.04 lacs
Madhusudan B Agrawal
Vice Chairman
3.62 cr
Yogesh Agrawal
Managing Director
15.63 cr
Chandrakanth M Khetan
Independent Director
11.87 lacs
Gaurang Shah
Vice President & CS
0
Rajesh M Agrawal
Joint Managing Director
15.63 cr
K H Viswanathan
Independent Director
9.23 lacs
Prabhakar Dalal
Independent Director
8.33 lacs
Anjana Grewal
Independent Director
7.49 lacs
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
Purchase of Stock-in-Trade
149.04
0%
 
100
Purchase of Stock-in-Trade
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceutical Products
1,493.94
84.28%
Pharmaceutical Products - Traded
237.42
13.39%
Other Operating Revenues - Export Incentives
38.93
2.20%
 
84.28
Pharmaceutical Products
15.72
Pharmaceutical Products
13.39
Pharmaceutical Products - Traded
86.61
Pharmaceutical Products - Traded
2.2
Other Operating Revenues - Export Incentives
97.8
Other Operating Revenues - Export Incentives
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,354 Cr
(Quarterly Results - Sep 2025)
Net Profit:
260 Cr
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 32,862 Cr (Mid Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

1.07%

stock-summary
Debt Equity

-0.16

stock-summary
Return on Equity

22.56%

stock-summary
Price to Book

7.59